Granules India AP facility clears USFDA inspection

Attention Investors

Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000. | Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors." | KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary." | ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

- EQUITY
  EQUITY
  PRICE
  
  Gainers & Losers
  
  Advances & Declines
  
  New Highs & Lows
  
  Index Movers
  
  Only Buyers/Sellers
  
  Out/Under Performers
- NEWS
  CORPORATE ACTIONS
  
  Announcements
  
  Book Closure
  
  Board Meetings
  
  Bonus Issues
  
  Rights Issues
  
  De-Listed Shares
  
  Market Turnover
  
  Change of Name
  
  Split of Face Value
- OTHER MARKETS
  FII Investments
  
  MF Investments
  
  ADR Prices
  
  World Indices
  
  Forex
  
  CORPORATE INFO
- VOLUME
  VOLUME
  Value & Volume Toppers
  
  Unusual Volume
  
  Bulk & Block Deals
  
  Sector Watch
- ANALYSIS
  ANALYSIS
  52 Week High Low
  
  Live Indices
  
  Exchange Holidays
  
  Index Constituents
  
  Historical Returns
  
  Circuit Breakers
- IPO
  IPO
  
  Forthcoming Issues
  
  Open Issues
  
  Closed Issues
  
  New Listing
  
  Basis of Allotment
  
  Draft Prospectus
  
  New Issue Monitor
  
  Best Performers
  
  Know IPO's / FAQ's

Tuesday, May 7, 2024

Asian Paints

2911.55

(-0.70%)

Axis Bank

1127.45

(-1.46%)

Bajaj Finance

6872.50

(0.17%)

Bajaj Finserv

1614.45

(0.18%)

Bharti Airtel

1284.85

(0.12%)

HCL Technologi..

1330.70

(-2.14%)

HDFC Bank

1506.40

(-1.08%)

Hind. Unilever

2379.60

(5.51%)

ICICI Bank

1131.75

(-1.48%)

IndusInd Bank

1452.60

(-3.05%)

Infosys

1440.75

(1.05%)

ITC

440.40

(1.33%)

JSW Steel

856.95

(-2.61%)

Kotak Mah. Ban..

1644.30

(1.20%)

Larsen & Toubr..

3432.80

(-0.85%)

M & M

2191.30

(-1.50%)

Maruti Suzuki

12367.10

(-0.53%)

Nestle India

2508.55

(2.06%)

NTPC

349.05

(-2.13%)

Power Grid Cor..

295.25

(-3.80%)

Reliance Indus..

2803.95

(-1.23%)

St Bk of India

801.95

(-0.72%)

Sun Pharma.Ind..

1515.15

(-0.95%)

Tata Motors

988.20

(-2.72%)

Tata Steel

164.20

(-2.03%)

TCS

3978.25

(1.47%)

Tech Mahindra

1292.20

(2.37%)

Titan Company

3276.25

(-0.16%)

UltraTech Cem.

9688.15

(-0.92%)

Wipro

463.45

(1.13%)

	Equity Analysis

	News Analysis

	Corporate Actions

	Other Market

	Company Profile

Share Holding Pattern

Your results on : Equity | News | Company-News

Granules India AP facility clears USFDA inspection	Share Back
(13 Apr 2024)
Granules India informed that its unit V facility located at Anakapally, Visakhapatnam, Andhra Pradesh, India underwent a United States Food and Drug Administration (USFDA) inspection from 8 April 2024 to 12th April 2024. This audit was a pre-approval inspection (PAI) and current good manufacturing practice (cGMP) audit for active pharmaceutical ingredients (APIs) and formulations (FDs); oncology and non-oncology. This facility manufactures APIs & formulations of oncology and non-oncology products. Granules India is primarily involved in the manufacturing and selling of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation intermediates (PFIs) and Finished Dosages (FDs). The pharma company's consolidated net profit rose 1.06% to Rs 125.65 crore on 0.82% increase in revenue from operations to Rs 1,155.58 crore in Q3 FY24 over Q3 FY23. The scrip declined 1.14% to settle at Rs 421.95 on Friday, 12 April 2024.
Top